All GLG News Analyses Filed Under: Oncology

Antisoma's AS 1409 has just entered a clinical phase I trial for patients with advanced melanoma and renal cancer. While efficacy results are years ago, this "immunotherapy" will be competing with many approved targeted agents in renal cancer ( Sutent, Nexavar, Torisel) and with many other immunotherapeutic...

Herceptin use in the adjuvant and netastatic setting of breast cancer is based on solid clinical data with proven efficacy and rather low and expected toxicity. Avastin use in the metastatic setting of breast cancer is a matter of debate because the efficacy is borderline while the short term and long...

Virtual Colonoscopy and stool analysis for DNA alterations for colon cancer, are being recommended for screening.

Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces the entry of AS1409 into clinical trials. A phase I trial has started in patients with renal cancer and melanoma. The trial has two parts. In the first, successive cohorts of patients will receive increasing doses of AS1409....

While the disease incidence (cervical carcinoma) is lower than many other cancers, thanks in part to successful screening, many of the remaining cases could be prevented by vaccinating EVERY female prior to the onset of sexual activity. Since this universal coverage is not likely, vaccinating males...

Camptosar is being made in Israel I would imagine, and the price differential compared to Pfizer's brand name drug is????

the "Record" trial showed that Novatis' m-Tor inhibitor, everolimus improved progression free survival as compared to placebo in patients with advanced renal cancer who failed several other therapies including Avastin ( Genentech), Nexavar ( Bayer) and/or Sutent ( Pfizer). With The field of targeted...

This is another issues that now arises in the use of combined hormone therapy. At least for postmenopausal women its use should be resticited in time and only used for symptom relief when nothing less is likely to work. Or, in theeapy in osteoporosis where there is no other choice of therapy ( not ...

In the accident of the cancer genome there will always be collateral damage. The difficulty is therefore distinguishing between mutations that are driving cell survival and proliferation (sinners) versus those which merely are passengers, neutral changes (sinned against) that arose at precisely...

Exciting data.  Target important and partially validated.  Santarus a competitor with an antisense approach.  Fibrogen Astellas trial of HIF prolyl hydroxylase inhibitor stopped due to a death.